

Supplementary table 1. Univariate analysis for various clinical endpoints

Endpoint	Characteristic	OR	95% CI	P-value
OS	Age	1.77	1.28-2.44	< 0.001
	Sex	0.77	0.52-1.14	0.188
	Histology	0.43	0.26-0.7	< 0.001
	Pre-DNA	1.65	1.2-2.26	0.002
	T stage	0.74	0.46-1.2	0.22
	N stage	2.23	1.64-3.05	< 0.001
	Overall stage	2.45	1.79-3.35	< 0.001
	Treatment	0.88	0.52-1.49	0.642
DMFS	Age	1.27	0.9-1.78	0.174
	Sex	0.8	0.53-1.22	0.303
	Histology	0.57	0.32-1.03	0.063
	Pre-DNA	2.06	1.47-2.89	< 0.001
	T stage	0.75	0.44-1.26	0.272
	N stage	2.67	1.9-3.75	< 0.001
	Overall stage	2.29	1.63-3.21	< 0.001
	Treatment	0.95	0.51-1.76	0.874
LRFS	Age	1.4	0.95-2.07	0.093
	Sex	1.37	0.9-2.09	0.142
	Histology	0.36	0.2-0.65	< 0.001
	Pre-DNA	0.99	0.65-1.52	0.969
	T stage	0.92	0.48-1.77	0.81
	N stage	1.27	0.85-1.9	0.236
	Overall stage	1.4	0.94-2.07	0.096
	Treatment	1.15	0.57-2.32	0.701

PFS	Age	1.47	1.14-1.9	0.003
	Sex	0.96	0.71-1.29	0.787
	Histology	0.48	0.31-0.74	< 0.001
	Pre-DNA	1.47	1.13-1.91	0.004
	T stage	0.73	0.5-1.09	0.125
	N stage	1.86	1.44-2.4	< 0.001
	Overall stage	1.84	1.43-2.38	< 0.001
	Treatment	0.88	0.57-1.36	0.572

Abbreviations: CI, confident interval; OR, odds ratio; OS, overall survival; DMFS, distant metastasis free survival; LRFS, locoregional relapse free survival; PFS, progression-free survival.